Business Description
Intensity Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US45828J1034
Total Employee Number:
7Description
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 100.44 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 14.9 | |||||
3-Year EPS without NRI Growth Rate | 16.1 | |||||
3-Year FCF Growth Rate | 13.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.98 | |||||
9-Day RSI | 72.33 | |||||
14-Day RSI | 66.6 | |||||
3-1 Month Momentum % | -32.46 | |||||
6-1 Month Momentum % | -65.93 | |||||
12-1 Month Momentum % | 980.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.86 | |||||
Quick Ratio | 4.86 | |||||
Cash Ratio | 4.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -68.9 | |||||
Shareholder Yield % | -151.06 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -169.22 | |||||
ROA % | -122.95 | |||||
ROIC % | -622.21 | |||||
3-Year ROIIC % | 171.73 | |||||
ROC (Joel Greenblatt) % | -10822.61 | |||||
ROCE % | -173.35 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.24 | |||||
Price-to-Tangible-Book | 1.24 | |||||
EV-to-EBIT | -0.27 | |||||
EV-to-EBITDA | -0.27 | |||||
EV-to-Forward-Revenue | 33.6 | |||||
EV-to-FCF | -0.33 | |||||
| Price-to-Net-Current-Asset-Value | 1.44 | |||||
| Price-to-Net-Cash | 1.56 | |||||
Earnings Yield (Greenblatt) % | -370.37 | |||||
FCF Yield % | -68.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INTS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Intensity Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6.919 | ||
| Beta | 2.919 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 9.19 | ||
| Volatility % | 218.62 | ||
| 14-Day RSI | 66.6 | ||
| 14-Day ATR ($) | 0.239369 | ||
| 20-Day SMA ($) | 4.28175 | ||
| 12-1 Month Momentum % | 980.6 | ||
| 52-Week Range ($) | 0.1853 - 11.0725 | ||
| Shares Outstanding (Mil) | 2.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intensity Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intensity Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 114 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 23 days | ||
| General meeting for 2026 | 2026-06-16 10:30 | 3.93 (+6.23%) | ||
| First quarter earnings results for 2026 | 2026-05-07 16:06 | 5.21 (-1.14%) | ||
| Annual report for 2025 | 2026-03-27 | 6.11 (-1.85%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 6.11 (-1.85%) | ||
| 0.04:1 Stock Split | 2026-02-19 | 6.13 (+10.21%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 0.57 (+4.24%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-05 07:00 | 0.27 (+0.18%) | ||
| Second quarter earnings results for 2025 | 2025-08-07 | 0.27 (-4.65%) |
Show
Entries
Intensity Therapeutics Inc Frequently Asked Questions
What is Intensity Therapeutics Inc(INTS)'s stock price today?
The current price of INTS is $4.87. The 52 week high of INTS is $11.07 and 52 week low is $0.19.
When is next earnings date of Intensity Therapeutics Inc(INTS)?
The next earnings date of Intensity Therapeutics Inc(INTS) is 2026-08-07 Est..
Does Intensity Therapeutics Inc(INTS) pay dividends? If so, how much?
Intensity Therapeutics Inc(INTS) does not pay dividend.
Guru Commentaries on NAS:INTS
No articles.
Press Release
Articles on Intensity Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers